The Swiss biotechnology company Mabylon has received two research grants from Target ALS and the ALS Association to support ...

A group of eight molecules in the blood can be used as a biomarker to distinguish ALS from other neurodegenerative conditions ...

Clene will have an in-person meeting with the FDA before the end of November to discuss a potential CNM-Au8 accelerated ...

Columnist Juliet Taylor reflects on how the power of music helped her and her late husband, Jeff, navigate the difficulties ...

A man with ALS became the first person to control an Amazon Alexa with his thoughts via an implanted brain-computer interface ...

Amprion was awarded a $100,000 research grant to support studies on the causes of sporadic ALS that could improve diagnosis ...

Fourteen years into an ALS diagnosis, columnist Dagmar Munn decides in a visit to the dermatologist that she's earned her ...

Ractigen's therapy candidate RAG-17 was safe across all tested doses and showed early signs of effectiveness in SOD1-ALS ...

For columnist Kristin Neva, whose husband, Todd, has ALS, everyday moments like her son's football game are filled with both ...

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

Certain rare genetic variants tied to Parkinson’s and other diseases raise the risk of developing ALS by more than three times, per a study.

A short course of treatment with RNS60, as an add-on to riluzole, extended the survival of ALS patients by about six months, ...